Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Dean F. Bajorin, Nicholas J. Vogelzang et al.|New England Journal of Medicine|2017Cited by 3.4k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun Vasant Balar, Joaquim Bellmunt, Daniel Castellano et al.|The Lancet Oncology|2017Cited by 1.3k
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upYves Fradet, Dean F. Bajorin, Joaquim Bellmunt et al.|Annals of Oncology|2019Cited by 484